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endogenous cost-effectiveness analysis policies aimed at lowering spending may
actually raise it. Second, reimbursement policy based on endogenous cost-effec-
tiveness levels may lead to adoption of more inefficient treatments. Under the
standard conditions when producer costs are unobservable, we provide a test for
these conditions using data on technology appraisals in the UK 1999-2005.
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OBJECTIVES: The paper is to improve the quality of life and health of the peoples of
the world by fostering and maintaining high standards of care in general practice/
family medicine and other clinicians. METHODS: By comparing the general prac-
titioners/family physicians with the clinicians of specialities, summarizing the
shortcomings of present health care services, the proposals for promoting health
care services around the world were suggested. RESULTS: The article initiates that
the values of general practice/family medicine should be fostered into other clini-
cians when all the clinicians take care of the patients in any conditions, critical or
ordinary, by adopting to the values of general practice/family medicine. While the
clinicians also take into account of their own specialities. CONCLUSIONS: In ap-
plying these proposals, a healthy world and high quality of life of the peoples of the
world will come soon! So the quality of life and health of the peoples of the world
can be promoted and enhanced.
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OBJECTIVES: The main objective of this study was to understand the appropriate-
ness of a GPs Longitudinal Database on exploring potential causal associations
among therapies and adverse events. We’ve focused on subjects treated with three
of the most widespread atypical antipsychotics drugs known as affecting patients’
lipidic profile and cardiovascular and diabetes risk.METHODS:Data were obtained
from CSD LPD, an Italian General Practitioner’s longitudinal database. Patients
with a first prescriptions of Aripiprazole, Olanzapine or Quetiapine during the pe-
riod January 2005 to December 2009 have been selected. For each patient, the first
prescription has been considered as the Index Date. The final study sample was
composed of patients that during the following three months had at least another
prescription of the same atypical antipsychotic. Patients have been followed-up for
a maximum of 12 months starting from three months after the Index Date.
RESULTS: Treatment groups were composed of 367 patients for Aripiprazole, 1825
patients for Olanzapine and 3088 patients for Quetiapine. The proportion of pa-
tients with an out of range value of Total Cholesterol and LDL was significantly
lower in Aripiprazole group. The same trend has been observed for the proportion
of patients with at least one recorded diagnosis of cardiovascular events and dia-
betes. The association between treatment and cardiovascular diagnosis presence
was still significant even when performing a multivariate logistic model adjusted
for age, gender and presence of a cardiovascular diagnosis during the year before
the Index Date (Odds Ratio Olanzapine VS. Aripiprazole: 1.76 [1.08 – 2.85]; Odds
Ratio Quetiapine versus Aripiprazole: 1.67 [1.03 – 2.70]). CONCLUSIONS: CSD LPD
database resulted to be appropriate in exploring potential causal associations
among treatments and potential adverse events both in terms of recorded diagno-
sis and in terms of recorded laboratory exams values even if, in this case, the
sample size was reduced.
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OBJECTIVES: To compare the prophylaxis patterns, incidence of venous thrombo-
embolism (VTE), major and minor bleeding and readmission over 90 days in hos-
pitalized medically ill patients.METHODS:A retrospective study (January 1, 2005 to
December 31, 2007) was conducted using a health insurance claims database. Eli-
gible patients were selected if they were continuously enrolled in their health plan
for at least 180 days prior to and 90 days following the index hospital discharge, for
which they were hospitalized with a medically ill diagnosis. Prophylaxis use was
defined as receiving low molecular weight heparin (LMWH) only, warfarin only,
unfractionated heparin (UFH) only, fondaparinux only, LMWH and warfarin, or
UFH and warfarin, from the index hospitalization date to 30 days after index hos-
pital discharge and before VTE events. Risk-adjusted venous thromboembolism
and major and minor bleeding events among patients with different thrombopro-
phylaxis patterns were compared. RESULTS: In patients who were identified as
medically ill (n12,077), 6,464 (53.52%) received anticoagulant therapy during their
hospitalization and until 30 days after discharge. Among these patients who re-
ceived prophylaxis, 2,137 (33.06%) received LMWH only, 693 (10.72%) received war-
farin only, 2168 (33.54%) received UFH only, 12 (0.19%) received fondaparinux only,
291 (4.50%) received LMWH and warfarin, and 325 (5.03%) received UFH and war-
farin. Among the 6 prophylaxis patterns, patients who received LMWH only were
associated with lower VTE (0.39% vs. 1.98%, p0.0001) and readmission rates (8.38%
vs. 13.68%, p0.0049) than those with LMWH and warfarin combination therapy. In
addition, the LMWH only group of patients had lower rates of major and minor
bleeding than the UFH and warfarin combination therapy group. CONCLUSIONS:
Despite existing guidelines, few medically ill patients receive anticoagulant pro-
phylaxis. Appropriate anticoagulant prophylaxis results in lower VTE event rates in
hospitalized medically ill patients.
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OBJECTIVES: To assess the real-world rate of appropriate prophylaxis use for inci-
dences of venous thromboembolism (VTE), and major and minor bleeding in hos-
pitalized medically ill patients. METHODS: A retrospective study (January 01, 2005
to December 31, 2007) was conducted using a health insurance claims database.
Eligible patients were selected if they were continuously enrolled in their health
plan for at least 180 days prior to and 30 days following the index hospital discharge
date, for which they were hospitalized with a medically ill diagnosis. Prophylaxis
use was defined as receiving low molecular weight heparin (LMWH) only, warfarin
only, unfractionated heparin (UFH) only, fondaparinux only, LMWH and warfarin,
or UFH and warfarin, from the index hospitalization admission date to 30 days after
index hospital discharge, and before VTE events. Risk-adjusted VTE and major and
minor bleeding events among patients with different thromboprophylaxis pat-
terns were compared. RESULTS: In patients who were identified as medically ill
(n12,947), 6,949 (53.67%) received anticoagulant therapy during their hospitaliza-
tion and until 30 days after discharge. Among those patients who received prophy-
laxis, 2,295 (33.03%) received LMWH only, 752 (10.82%) received warfarin only, 2,313
(33.29%) received UFH only, 12 (0.17%) received fondaparinux only, 309 (4.45%)
received LMWH and warfarin, and 353 (5.08%) received UFH and warfarin. Com-
pared with patients who received LMWH only, patients who received the combi-
nation therapy of LMWH and warfarin had significantly more VTE events (1.14% vs.
0.32%, p0.0099) and higher readmission rates (6.11% vs. 3.05%, p0.0093), while
patients who received the combination therapy of UFH and warfarin had signifi-
cantly higher minor bleeding (11.70% vs. 6.06%, p0.0002) and readmission rates
(7.49% vs. 3.05%, p0.0001). CONCLUSIONS: Appropriate anticoagulant prophy-
laxis use results in lower VTE event rates as well as lower major and minor bleeding
rates in hospitalized medically ill patients. More effort is required to improve the
use of appropriate thromboprophylaxis.
PCV4
COMPARATIVE EFFICACY OF MAINTENANCE OF SINUS RHYTHM VERSUS RATE
CONTROL STRATEGIES IN THE TREATMENT OF ATRIAL FIBRILLATION –
SYSTEMATIC REVIEW AND META-ANALYSES
Wojciechowski P1, Stozek A1, Machowska A1, Gaweska M1, Lis J2, Glasek M2, Rys P1,
Wladysiuk M1, Plisko R1
1HTA Consulting, Krakow, Poland, 2Sanofi Poland, Warszawa, Poland
OBJECTIVES: The aim of this study was to assess whether restoration and mainte-
nance of sinus rhythm is associated with clinically meaningful improvement in
patients with atrial fibrillation (AF) or atrial flutter (AFI). METHODS: Assessment
was based on randomized controlled trials (RCTs) identified by means of system-
atic review, carried out according to the Cochrane Collaboration guidelines. Studies
met the inclusion criteria if they directly compared two treatment strategies, i.e.
maintenance of sinus rhythm (MSR) including first generation antiarrhythmic
drugs (FGAAD; mainly amiodarone, sotalol, dizopiramide, propafenone, dofetilide,
flecainide) vs. rate control (RC) including pharmacologic agents (calcium channel
blockers, beta blockers, cardiac glycosides), with regard to clinically meaningful
endpoints. The most important medical databases (EMBASE, MEDLINE and CEN-
TRAL) were searched until January 2011. Two reviewers independently selected
trials, assessed their quality and extracted data. RESULTS: Eight RCTs directly
comparing MSR vs RC were identified and included. Meta-analysis of those studies
showed that significantly more patients assigned to MSR were in sinus rhythm at
the end of study as compared to RC strategy (RB  4.49 [2.49; 8.09]; NNT13-
37months  2 [2-4]). However, it did not lead to any benefit regarding clinically
meaningful endpoints. Comparison between both treatment strategies revealed no
statistically significant difference with respect to risk of overall mortality (RR 1.06
[0.96; 1.17]), cardiovascular mortality (RR 1.01 [0.88; 1.16]), stroke (RR 1.02 [0.82;
1.26]), systemic embolism (RR 0.78 [0.35; 1.71]), heart failure (RR 0.94 [0.80; 1.09])
or bleeding (RR 1.10 [0.65; 1.84]). CONCLUSIONS: In this analysis, restoration and
maintenance of sinus rhythm achieved with FGAAD was not associated with clin-
ically meaningful improvement in patients with AF or AFl. MSR strategy neither
improved survival nor decreased morbidity as compared to RC. The reevaluation of
current criteria of antiarrhythmic drug assessment should be considered.
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